替考拉宁与去甲万古霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染患者的临床研究

Clinical research of teicoplanin and norvancomycin in the treatment of lung infected patients caused by MRSA

目的探讨替考拉宁与去甲万古霉素治疗ICU耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染患者的疗效,为治疗MRSA肺部感染提供参考依据。方法选取2007年11月-2013年9月ICU收治的73例MRSA肺部感染患者,将其分为两组,治疗组37例患者给予替考拉宁治疗,对照组36例患者给予去甲万古霉素治疗,分析比较两组患者治疗后的疗效,采用SPSS 12.0软件进行统计分析。结果治疗组总有效率为89.19%、病原菌清除率为91.89%、不良反应发生率为21.62%,对照组总有效率为69.44%、病原菌清除率为72.22%、不良反应发生率为50.00%,治疗组总有效率、病原菌清除率较高,不良反应发生率较低,两组差异有统计学意义(P<0.05)。结论替考拉宁与去甲万古霉素均可有效治疗ICU患者MRSA肺部感染,但替考拉宁的疗效更佳,清除率较高,不良反应少。

OBJECTIVE To study the curative effect of teicoplanin and norvancomycin in the treatment of lung infected patients caused by MRSA so as to provide references for curing MRSA infected patients.METHODS Totally 73 cases of ICU patients with lung infections causing by MRSA from Nov.2007 to Sep.2013 were divided into two groups：37cases in the treatment group,which received teicoplanin,and 36 cases in the control group given norvancomycin.The curative effect of the two groups were compared and analyzed by SPSS 12.0software.RESULTS The total effective rate in the treatment group was 89.19%,and the bacteria clearance rate was 91.89%,the incidence of adverse reactions was 21.62%.While in the control group,the total effective rate was 69.44%,the bacteria clearance rate was 72.22%,and the incidence of adverse reactions was 50.00%.The results showed that the treatment group had a higher total effective rate and bacteria clearance rate,and lower incidence of adverse reactions.The differences between the two groups were significant（P〈0.05）.CONCLUSION Teicoplanin and norvancomycin are effective in treating lung infections caused by MARA in ICU patients.But teicoplanin is comparatively better in efficacy,higher in bacteria clearance rate and fewer in adverse reactions.